Cerebroprotein Hydrolysate

Cerebroprotein hydrolysate is a unique neurotrophic peptidergic mixture produced by standardized enzymatic breakdown of lipid-free porcine brain proteins. It acts like endogenous neurotrophic factors as it consists of short biological peptides. Neurotrophic activity can be detected within 1 day after a single injection.

Cerebroprotein hydrolysate-augmented proliferation, differentiation and migration of adult sub ventricular zone (SVZ) neural progenitor cells results in an increased number of neural progenitor cells and neuroblasts to contribute to neurogenesis. This may be the mechanism for a beneficial effect in acute ischaemic stroke and traumatic brain injury. Enhancement of neuronal survival is produced through an effect on calpain. The hyper-activation of calpain is implicated in a number of neurodegenerative disorders. Calpain is inhibited by cerebroprotein hydrolysate.

Therapy Area: Neurodegenerative, Neurodevelopment & Mental Health
Form: Injection
Packaging: Pack of 6 Vials


Cerebroprotein Hydrolysate 60mg


Cerebroprotein Hydrosylate enhances neurogenesis, neuronal survival, provides neuromodulatory action, increases/modulates neuronal plasticity and neuronal repair and has neuroimmunotrophic actions and thus has a unique neurotrophic activity. Cerebroprotein hydrosylate helps in Neuronal differentiation and protection against ischaemic and neurotoxic lesions. It regulates and improves neuronal metabolism. It reduces excitotoxic damage, blocks over-activation of calcium dependent proteases, and scavenges free oxygen radicals. It has been found in animal studies that early intervention with cerebroprotein hydrosylate reduces blood-brain and blood-cerebrospinal fluid barrier permeability changes, attenuates brain pathology and brain edema, and mitigates functional deficits caused by traumatic brain injury. It improved brain bioelectrical activity, i.e. reduced EEG ratio by increasing fast frequencies and reducing slow activities and also improves cognitive performance in tasks, evaluating attention and memory functions in post-acute traumatic brain injury patients


  • Traumatic brain injury
  • Acute ischaemic stroke
  • Vascular dementia
  • Extrapontine myelinolysis
  • Alzheimer’s disease


Adult: 60 – 180mg for 10 to 20 days


This information is for registered medical practitioner only. Anyone other than medical practitioner should consult medical practitioner before using this product.

Enquire About CEREKLAS

Fill the form below and we will get in touch with you

    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.